Sohayla Elmorsi

Dr. Sohayla Elmorsi

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2026 in Cancers
Verified
Journal Article
Open access
PDF file
BEBassant El-Mosalamy
Bassant El-Mosalamy
Hossam Magdy BalahaHossam Magdy Balaha
Hossam Magdy Balaha
SESohayla Elmorsi
Sohayla Elmorsi
DGDibson Gondim
Dibson Gondim
KLKhaldon Lweesy
Khaldon Lweesy
Ayman El-BazAyman El-Baz
Ayman El-Baz
The diagnosis of colorectal cancer encompasses nine complementary modalities: stool-based screening, blood-based biomarkers, cross-sectional imaging, endoscopic evaluation, histopathology, liquid biopsy, molecular and genetic profiling, microbiome analysis, and nanotechnology-based diagnostics. This narrative review synthesizes 160 references spanning seven task-specific artificial intelligence domains, including computer-aided detection, optical diagnosis, invasion depth prediction, computational pathology and radiogenomics, metastasis forecasting, neoadjuvant treatment response prediction, and surgical workflow analysis. We propose a conceptual multimodal pipeline comprising data ingestion, preprocessing and harmonization, feature representation, multimodal fusion, forecasting, explainability, and validation. A structured evidence grading framework classifies each clinical task by evidence level, consistency, and clinical readiness. We further catalog public datasets, challenge benchmarks, and five reporting standards: TRIPOD-AI, CONSORT-AI, SPIRIT-AI, DECIDE-AI, and CLAIM. Computer-aided detection and optical diagnosis demonstrate the highest maturity with Level 1 evidence from randomized controlled trials, while computational pathology, radiogenomics, and metastasis prediction remain at Level 2 with retrospective validation (internal or external). Microbiome screening, nanotechnology diagnostics, and surgical phase recognition are exploratory. The principal barriers to clinical adoption are domain shift, data scarcity, calibration, prospective validation, and workflow integration. We conclude that clinically useful artificial intelligence requires robust external validation, uncertainty quantification, explainable outputs, standardized reporting, and a structured translational pathway from retrospective evidence through regulatory clearance to post-deployment monitoring.